fda reversal on knockoff glp 1 restricts non-approved compounded GLP-1 weight loss products Exploration of the potential association

Here, the incidence rate in studies was very low and the study data have shown different results, so that further research is warranted on this observation

A: July 1, 2026

Not GLP-1 agonists

The findings indicate that: 67% of Omada members were persistent on their medication at one year and experienced weight loss comparable to clinical trials Average weight loss at one year in the program was 18.4% for members persistent on medication and 13.1% for members who discontinued before one year In terms of engagement, members completed more than 10 actions a week on average This data suggests that providing the right kind of support to promote GLP-1 persistence can help patients achieve clinical trial-level weight loss, setting the stage for cardiometabolic disease risk reduction

If you have a history of eating disorders, you are entitled to a referral to both an eating disorders specialist and an obesity medicine specialist ( Mozaffarian et al., Am J Clinical Nutrition, 2025 )

[2] Diuretics also directly increase urine output